Borah Pobitra, Deb Pran Kishore, Deka Satyendra, Venugopala Katharigatta N, Singh Vinayak, Mailavaram Raghu Prasad, Kalia Kiran, Tekade Rakesh Kumar
Pratiksha Institute of Pharmaceutical Sciences, Chandrapur Road, Panikhaiti, Guwahati-781026, Assam, India.
Department of Pharmaceutical Sciences, Faculty of Pharmacy, Philadelphia University, PO Box 1, Amman 19392, Jordan.
Curr Med Chem. 2021;28(2):284-307. doi: 10.2174/0929867327666200908113642.
The COVID-19 pandemic continues to wreak havoc worldwide due to the lack of risk assessment, rapid spreading ability, and propensity to precipitate severe disease in comorbid conditions. In an attempt to fulfill the demand for prophylactic and treatment measures to intercept the ongoing outbreak, the drug development process is facing several obstacles and renaissance in clinical trials, including vaccines, antivirals, immunomodulators, plasma therapy, and traditional medicines. This review outlines the overview of SARS-CoV-2 infection, significant recent findings, and ongoing clinical trials concerning current and future therapeutic interventions for the management of advancing pandemic of the century.
由于缺乏风险评估、快速传播能力以及在合并症中引发严重疾病的倾向，新冠疫情仍在全球肆虐。为了满足拦截当前疫情的预防和治疗措施需求，药物研发过程在临床试验中面临诸多障碍并迎来复兴，这些措施包括疫苗、抗病毒药物、免疫调节剂、血浆疗法和传统药物。本综述概述了新型冠状病毒感染的概况、近期的重要发现以及当前正在进行的关于管理本世纪不断蔓延的大流行的治疗干预措施的临床试验情况。
